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Background:  Photodynamic  therapy  (PDT) is  used  to treat  early  proximal  bronchial  cancer  during  a ﬂexible
bronchoscopy.  The  technique  relies  on the  excitation  of  a  photosensitizer  by an  appropriate  wavelength,
which  is  delivered  into  the  bronchus  in  close  contact  with  the  tumor.
Objective:  To assess  methylene  blue  (MB)  as a  PDT  agent  for  the  treatment  of  respiratory  tract  cancer  in
animal  models.
Methods: MB-induced  PDT  was  performed  on 7  subcutaneous  NCI-H460  lung  adenocarcinoma  xenografts
in nude  mice  and  9  induced  squamous  cell  cancer  in  the  hamster  cheek  pouch  model.  In  mice,  PDT  was
carried  out  on  right-sided  tumors  after intratumoral  injection  of methylene  blue  1%  (w/v)  and  illumination
at  630  nm at 200  J/cm  (Diomed  PDT  630),  with  the  left  tumor  used  as  control  (illumination  alone  or  MB
alone).  The  tumoral  volume  was assessed  before  and  15  days  after  PDT.
Results:  Fourteen  xenografts  were  treated  in  mice,  including  seven  treated  with  MB-PDT,  producing  a
52%  mean  tumor  volume  regression  (1568  mm3 vs.  544  mm3) compared  to seven  control  cases  in  which
tumor  volume  increased  (p = 0.007;  Mann-Whitney  test).  Nine  cheek  pouch  induced  carcinomas  were
treated  in  the hamster  group,  with  a mean  volume  decrease  of  85.8%  (from  44.8% to  100%)  (initial
3 3mean  volume  = 210 mm vs.  post PDT  mean  volume  =  97  mm ). Histology  analysis  showed  4/9 complete
responses.
Conclusion:  Intratumoral  MB appears  efﬁcient  as PDT  agent  for cancer  treatment  in animal  models.  Further
studies  are  needed  to assess  the  safety  and efﬁcacy  of  MB-associated  PDT  for the treatment  of  lung  cancer
in  humans.
© 2016  The  Authors.  Published  by  Elsevier  B.V.  This  is  an  open  access  article  under the  CC  BY-NC-ND
license (http://creativecommons.org/licenses/by-nc-nd/4.0/).. Introduction
Antitumor photodynamic therapy (PDT) is a treatment tech-
ique based on the association of photosensitive molecules (i.e.,
hotosensitizer) and an appropriate light wavelength for the pho-
osensitizer [1]. The action of the light, at the correct wavelength,
nduces the formation of singlet oxygen 1O2 in the cell that
bsorbed the photosensitizer, in the presence of oxygen. A singlet
xygen is a powerful oxidant that reacts with numerous cellular
∗ Corresponding author at: Clinique Pneumologique, Rouen University Hospital,
rue de Germont, 76000 Rouen, France.
E-mail addresses: mathieu.salaun@univ-rouen.fr, mathieu.salaun@chu-rouen.fr
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/).constituents, leading to direct cellular damage such as necrosis or
apoptosis [2–4]. In humans, the photosensitizer is usually injected
intravenously and concentrates in the tumor cells. Apart from
potential undesirable side-effects, the principal inconvenience of
systemic administration of the photosensitive agent is represented
by the variable accessibility and concentration of the agent in the
target cells.
Methylene blue (MB), a powerful ﬂuorophore, possesses pho-
todynamic properties at 630 nm.  Photo-excited at 200 J/cm2, MB
generates oxygen singlets creating the photodynamic effect [5]. In
an earlier study, PDT using local application of MB was success-
fully tested in three patients with inoperable esophageal cancer
[6]. In nude mice with colic tumor cell xenografts, this treatment
under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.
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as shown to be efﬁcacious with a complete response rate of 79%
fter one course of therapy [7].
Our hypothesis was that the local application of MB  coupled
ith phototherapy was also efﬁcacious in the treatment of cancer-
us lesions of the respiratory tract. The objective of our study was to
emonstrate the efﬁcacy of PDT coupled with the local application
f MB,  using two tumor models, the bronchial cancer cell xenografts
n nude mice and the hamster cheek pouch cancer model.
. Material and methods
.1. Study design
The study was designed to demonstrate the potential effect of
ethylene blue as a photosensitizer in cancer of the respiratory
ract. First we used the NCI-H460 lung cancer cell line, which is
erived from pleural effusion of a patient with large cell lung car-
inoma [8–11], for the xenograft model in nude mice. Secondly,
e used the cheek-pouch model, which represents a carcinogen-
nduced cancer model that recapitulates the natural evolution of
 squamous carcinoma, from reserve cell hyperplasia to invasive
arcinoma [12,13].
.2. Animals
The animals were housed in groups of three in pre-sterilized
ages placed in a positive/negative ventilation housing system
PNCT3HR30EZ model, Allentown Inc., Allentown, New Jersey,
SA). The ambient temperature was 22 ◦C. The circadian rhythm
as maintained. The animals had unlimited access to food and
ater. The study started following 5 days of acclimatization.The
nimal experiment was undertaken in accordance with ethics rules
f the University of Rouen and those of the regional committee for
nimal ethics (N/03-12-10/25/12).
.2.1. The mice
Twelve female nude mice (Nu/Nu, Janvier, Le Genest Saint Isle,
rance), weighing 10 g and aged 6 weeks, were used for the NCI-
460 cell xenografts. Each mouse received, under isoﬂurane gas
nesthesia (Abbott Laboratories, Chicago, USA), a subcutaneous
njection of NCI-H460 cells in each ﬂank. Each injection (100 l)
ontained 3.106 cells/100 l.
.2.1.1. NCI-H460 cell preparation. The cells were cultured in a
PMI 1640 medium containing 10% fetal bovine serum. The culture
edium was enriched with antibiotics: penicillin (500 U/ml), strep-
omycin (0.1 mg/ml), and neomycin (0.2 mg/ml). The cells were
onserved at 37 ◦C in a 5% CO2 atmosphere.
The adherent NCI-H460 cells were washed with PBS. They were
hen exposed to a solution of 0.25% trypsin and 0.2% EDTA in an
ncubator for 5 min. The trypsinization was stopped via a medium
ontaining 10% fetal bovine serum.
The cells in suspension were centrifuged at 500 g and 4 ◦C for
 min. The supernatant was withdrawn, and the cells were re-
uspended in a medium containing 10% fetal bovine serum. The
ells were re-suspended at a concentration of 3.106/100 l in a
PMI medium.
.2.1.2. Treatment of the xenografts in the mice. The lesions that
eveloped on the right ﬂank received a photodynamic therapy (MB-
DT = local methylene blue + illumination), while the lesions on the
eft ﬂank received either a local injection of MB  alone or, solely,
llumination using a diode laser.ynamic Therapy 15 (2016) 109–114
2.2.2. The hamsters
2.2.2.1. Carcinogenesis of the hamster’s cheek pouch. Carcinogenesis
was obtained via an implant impregnated with dimethylbenzan-
thracene (DMBA) (Sigma Aldrich, Saint-Louis, USA) according to
the technique described by Heller [12]. The implant was  positioned
in the right cheek pouch under general anesthesia via intraperi-
toneal injection of a mixture of ketamine 30 mg/Kg (Laboratoire
Merial, Lyon, France) and xylazine 10 mg/Kg (Laboratoire Bayer,
Leverkusen, Germany) following isoﬂurane gas induction (Abbott
Laboratories, Chicago, USA).
According to the method of Wani [13], 4 weeks following
implantation, the right cheek pouches were everted and stained
with a solution of arecaidine (Sigma Aldrich Laboratory, Saint-
Louis, USA) at 1 g/l of mineral oil (Aguettant Laboratory, Lyon,
France), with three applications per week.
2.2.2.2. Treatment of the cheek cancer lesions. Nine male Syrian
hamsters, (Golden Syrian Hamsters, Janvier, Le Genest Saint Isle,
France), aged 6 weeks (100 g), were included in the protocol of MB-
PDT. The methylene blue was injected into the cancer lesion in the
right cheek pouch followed by illumination with the phototherapy
device.
2.3. The photodynamic therapy material
The device consisted of a laser source DIOMED 630 PDT
(DIOMED, Cambridge, Great Britain) and a ﬁberoptic cylindrical dif-
fuser (PDT-DCYL410 and 420, DIOMED, Cambridge, Great Britain).
The silica ﬁber had a proximal connection for a conventional SMA
connector to the laser source and a distal cylindrical diffuser tip,
designed to diffuse uniform light energy along the length of the
distributor.
2.4. The photodynamic therapy
The treatment was administered under general anesthesia
via intraperitoneal injection of a mixture of ketamine 30 mg/Kg
(laboratoire Merial, Lyon, France) and xylazine 10 mg/Kg (Bayer,
Leverkusen, Germany) following isoﬂurane gas induction (Abbott
Laboratories, Chicago, USA). For mice, the treatment was started
when the tumor that developed in either one of the ﬂank had
reached a minimal initial volume of 500 mm3. All hamsters pre-
senting with macroscopic cheek pouch lesions were sampled for
histological analysis to ensure that all lesions corresponded to inva-
sive carcinomas.
On Day 0, the lesions were photographed and measured. The
initial tumor volume of each lesion was calculated (initial tumor
volume VTi = A × B2/2, where A was the largest diameter and B the
smallest diameter).
According to the size of the lesion, 50–150 l of 1% (v/w) methy-
lene blue (concentration 31.3 mM),  (Aguettant laboratory, Lyon,
France) was injected into the cancerous lesion. The methylene blue
was injected gently using a 29 Gauge needle and 0.5 ml  syringe
(Penta®—ﬁne R.0, Campli, Italy) in the center of the tumor, either
in the mouse and the hamster models. The injection (50–150 l)
induced immediate blue coloration of the tumor and was stopped
when the whole cutaneous surface of the lesion turned blue, in
order to avoid spreading of the dye beyond the visible lesion.
We used 20 mm long cylindric diffusers to treat the lesions in the
mice and 10 mm  cylindric diffusers for the lesions in the hamsters.
After ﬁber calibration, the total power delivered by the diffusers
was set to 600 mW or 400 mW,  for the 20 mm and 10 mm cylindric
diffusers, respectively. The total illumination time was  500 s and
750 s, for hamster and mice’s lesions, respectively. The PDT ﬁber,
delivering 200 J/cm optical energy density, was  applied on the sur-
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Table  1
Evolution of nude mice H-460 xenograft tumors after treatment with methylene-blue associated photodynamic therapy, illumination alone or intra-tumoral methylene blue
injection alone.
Nude mice H-460 xenografts TUMORAL LESION TUMOR VOLUME (mm3)
Day 0 Day 5 Day 10 Day 15
Mouse 1 RIGHT: PDT + MB  3564 1270.5 4512.5 1666
LEFT:  MB  alone 3726 4151.5 15,300 20,808
Mouse  2 RIGHT: PDT + MB  1440 486 320 907.5
LEFT:  MB  alone 1656 3901.5 4536 907.5
Mouse  3 RIGHT: PDT + MB  2944 352 256 405
LEFT  MB  alone 1267.5 4630.5 4630.5 4630.5
Mouse  4 RIGHT: PDT + MB  864 486 544 Dead
LEFT:  Illumination alone 196 196 7488
Mouse  5 RIGHT: PDT + MB  320 220.5 100 320
LEFT:  Illumination alone 2025 3564 4600 8437.5
Mouse  6 RIGHT: PDT + MB  1960 1089 29.9 Dead
LEFT:  Illumination alone 320 1859 778.2
Mouse  7 RIGHT: PDT + MB  1568 87.5 750 Dead
LEFT:  Illumination alone 1666 1296 800
Table 2
Evolution of Hamster cheek-pouch tumors after treatment with methylene-blue associated photodynamic therapy.a
Hamster cheek-pouch TUMOR VOLUME (mm3)
Day 0 Day 5 Day 10 Day 15
Hamster 1 56 22.5 6 0
Hamster 2 1331 735 Euthanized
Hamster 3 18 0.5 0.5 Sacriﬁcedb
Hamster 4 75 22.5 18 Sacriﬁcedb
Hamster 5 22.5 1 0.75 Sacriﬁcedb
Hamster 6 352 56 112.5 Sacriﬁcedb
Hamster 7 0.5 0.25 0 0
Hamster 8 0.75 5 10 0
Hamster 9 40 13.5 0 0
Abbreviations: PDT; Photodynamic therapy; MB;  Methylene Blue.
a Only the right cheek pouch in each hamster was considered for the tumoral induction, and therefore, only this cheek pouch was treated with methylene-blue photodynamic
therapy.
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umor  volume was  decreasing. Complete response was obtained in hamster 1 at Da
ace of the lesion and moved on all of the tumoral surface, with
llumination time of 50 s on each spot, for a total of 750 s or 500 s.
.5. Therapeutic evaluation
The treatment of the lesions was evaluated on Day 5, 10, and 15.
Each lesion was photographed and measured as described
bove, following isoﬂurane gas induction, allowing for post-
reatment tumor volume assessment on Day 5, 10, and 15. The ﬁnal
umor volume on Day 15 was called the Vtf. The aspects of the lesion
ere also noted (necrotic, hemorrhagic, or indurated).
At the end of the protocol, the animals were euthanized by an
ntra-cardiac injection of thiopental (1 ml,  Hospira laboratory, Lyon,
rance). The lesions were excised, measured, weighed, and con-
erved in formalin solution (4%, Labonord laboratory, Templemars,
rance) for 48 h before histological examination.
.6. Statistical analysisThe relative variation of tumor volume (V = [Vtf-VTi]/VTi) was
ompared between the group of lesions treated with PDT and the
ontrol lesions, in mice, using the non-parametric Mann-Whitney
est. A p value <0.05 was considered signiﬁcant.able to analyse the histological damages of MB-PDT on the residual lesions, as the
Hamster 2 has been euthanized between Day 5 and Day  10 for ethical reason.
3. Results
3.1. The nude mice
The 12 nude mice developed neoplastic lesions on the two ﬂanks
following the xenograft of NCI-H460 cells. Five mice died during
the course of the experiment, without evaluation of the therapeu-
tic effects. The cause of the death occuring before PDT cannot be
precised. Seven mice remained evaluable for efﬁcacy testing of the
photodynamic therapy (PDT) on their right lesion. Fifteen days after
the xenograft, the initial mean volume was 1679 mm3 (median
1504 mm3). Among them, as control, 3 animals received an injec-
tion of methylene blue alone on their left lesion, and 4 animals
received illumination alone on their left lesion.
3.1.1. Macroscopic analysis
Table 1 show the evolution of tumor volume during follow-up
after treatment administration, either with MB-PDT, or with MB  or
illumination alone.Two  days after the treatment with MB-PDT, 2 mice devel-
oped skin necrosis on the treated lesion. Spontaneous healing was
observed before Day10. Three mice died on Day 10 and Day 11 after
MB-PDT (Table 1).
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The right lesions treated with MB-PDT regressed 52% on average
1568 vs. 544 mm3).
The relative variation of tumor volume (V) differed signiﬁ-
antly between the lesions treated with MB-PDT and the control
esions (−73% vs.  +76%, p = 0.007, Mann-Whitney test) (Table 3).
.1.2. Histological analysis
Histological analysis revealed cancerous lesions in all cases.
ecrotic areas were found in the samples taken both from the right
esions (treated with PDT), and the left lesions (controls).
.2. The hamsters
The initial median volume of the tumor that developed in
he cheek pouches was 40 mm3 (min = 0.5 mm3; max  = 1331 mm3).
even lesions presented with an initial volume less than or equal
o 75 mm3 (Table 2).
No animal lost weight during the treatment period, and there
ere no complications such as death or infection.
.2.1. Macroscopic analysis of the lesions treated with MB-PDT
The treated lesions presented with a necrotic appearance, at
imes hemorrhagic as of Day 5. The tissue adjacent to the treated
esion did not show any abnormality.
Table 2 shows tumor volume evolution of the cancerous lesions
f the cheek pouch following treatment, from Day 0 to Day 15. The
ize of the lesions decreased 85.5% on average (95%CI = [45–100]),
nd 94.2% (95%CI = [76–100]) for lesions less than 75 mm3. One
ealthy cheek pouch underwent MB-PDT, as control, showing a
ecrotic zone in the area in which the treatment was administered..2.2. Histological analysis
We  found residual cancer cells in 5 out of 9 animals treated,
hile a complete histological response was observed in the other
ig. 1. Histological slices from hamster’s cheek pouch after PDT (all animals were euth
DT;  A/epithelial ulceration (X5 magniﬁcation); B/subepthelial ﬁbrotic changes (X20); C/
lue-induced PDT showing inﬂammatory inﬁltrates with areas of liquefactive necrosis wynamic Therapy 15 (2016) 109–114
4 animals. As shown in Fig. 1, different histological abnormalities
were identiﬁed: areas of vascular necrosis, ﬁbrosis, and sub-acute
inﬂammation.
Healthy cheek pouches treated with PDT also showed alter-
ations at the histological level, notably inﬂammatory inﬁltrates
with areas of suppurative necrosis and diffuse muscular alterations
(Fig. 1C).
4. Discussion
Methylene blue, used in situ by intratumoral injection, and
associated with an immediate illumination of 630 nm at 200 J/cm,
appears to be a powerful photodynamic agent. In this study, it
was able to induce a signiﬁcant volume reduction of the cancer-
ous lesions treated, whether it was  subcutaneous adenocarcinoma
xenografts, in mice (in 6 out of 7 treated lesions), or cancerous
lesions induced in the hamsters’ cheek pouch, in which histological
complete response has been obtained in 4 out of 9 animals.
We observed a 73% decrease in tumor volume for the lesions
treated with photodynamic therapy at 630 nm and 200 J/cm cou-
pled with an intratumoral injection of MB  1%. These results were
consistent with those obtained by Orth in nude mice [7], despite
the fact that the size of the lesions (320–3564 mm3) was  more het-
erogeneous and larger in our study, and that the amount of energy
delivered was 200 j/cm, vs. 100 j/cm delivered in Orth’s study. In
spite of this difference, we  did not note any irreversible or lethal
side-effects following this treatment, with 2 mice showing skin
necrosis in tumoral areas, followed by complete healing in less than
8 days. In the hamsters showing complete response, the histological
analysis of the treated tumors revealed inﬂammatory inﬁltrates as
well as areas of tissue/vascular necrosis and chorion ﬁbrosis com-
patible with a photodynamic effect identical to that obtained with
the classical photosensitizing agents, such as porﬁmer sodium [5].
anatized on Day 15). A to C: squamous carcinomas after methylene blue-induced
vascular necrosis (X20); D: modiﬁcation of healthy control pouch after methylene
ith pus formation and diffuse muscular alterations (X10).
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Table  3
Evolution of xenograft mean tumor volume (mm3) between Day0 and Day15 according to the treatment received (n: number of mice).
MB-PDT MB  alone Illumination alone
Day0 1808.6 (n = 7) 2216.5 (n = 3) 1051.7 (n = 4)
Day5 570.2 (n = 7) 4227.8 (n = 3) 1728.7 (n = 4)
Day10 1191.6 (n = 7) 8155.5 (n = 3) 3416.5 (n = 4)
8.8 (n 
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bbreviations: MB-PDT: Methylene blue—associated photodynamic therapy; MB:  m
Previous studies have shown that direct intra-tumoral injection
f the dye results in high intra-tumoral concentration of the sen-
itizer. In their study, Mannino et al. [14] demonstrated a similar
umoral uptake according to intra-tumoral or intra-veinous admin-
stration of a sensitizer (m-THPC (Temoporﬁn)), and the absence
f extra-tumoral spreading of the dye. In our study, the evalua-
ion of the dye distribution relies on the visual appreciation of the
ethylene blue on the tumoral surface. Because MB coloration dis-
ppears rapidly from the tumor after treatment, the distribution of
he dye in the inner side of the tumor cannot be evaluated at the
ime of residual tumor excision. Therefore, the homogeneity of the
hotosensitizer distribution into the tumor cannot be controlled,
hich represents a limitation of the study, and may  explain why
o complete response was obtained in the mouse model.
The technique used in the present study involves the direct
njection of the dye in the center of the tumor until the whole
urface of the lesion turned blue, which also rises the ques-
ion whether a mechanical effect due to the injected volume
f the dye may  have affected the tumor growth. This appears
mprobable in the present study as none of the tumor injected
ith MB  without illumination showed a decrease in tumor vol-
me  with time. Five mice died before the PDT treatment and
 mice died between D10 and D15 after treatment (Table 1).
he delay between MB  injection and death suggests that death
ere not due to an immediate toxic effect of the MB injection,
ut rather to the tumoral progression of non-treated (i.e. con-
rol) lesion. Altogether, this suggests that the injection of the dye
nto the lesion did not affect the tumor by a reduction of the
umoral vascular supply due to compression or by a direct toxicity
ffect.
As far as healthy tissue is concerned, treatment with MB-PDT
esulted in histologically conﬁrmed necrotic lesions, consistent
ith those observed with PDT associated with photosensitizers
ystemically applied [15]. This indicates that MB-PDT may  have
on-speciﬁc effects on cancer, compared to the surrounding tissue.
On the other hand, PDT using intratumoral MB  may  have sev-
ral advantages: (a) because methylene blue is applied locally,
ts utilization would not require the skin protection measures
eeded for UVA-UVB and visible sunlight exposure, as with most
ystemic PDT agents; (b) the local application may  allow for bet-
er access of the photosensitizing agent to the tumor; (c) the
ost of methylene blue is currently very low, and methylene blue
ould be even more cost-effective for the health system since it
ould not require any adjunct prescriptions (protective creams,
ospitalization, etc.). However, as the intratumoral homogeneity
istribution of the photosensitizer maybe critical, the evalua-
ion of efﬁcacy and of potential advantages of local utilization of
B-PDT in human tumors will require speciﬁc dedicated stud-
es.
For future use in humans, the intratumoral injection of MB
mplies a precise localization of the treatment areas, as well as
 technique of application that would limit the diffusion of the
ye to the pathological areas. This strategy could be feasible for
he proximal respiratory tract where the lesions could be pre-
isely detected and targeted for dye injection, using endoscopic
echniques able to precisely localize the lesions, such as autoﬂu-= 3) 8437.5 (n = 1)
ene blue.
orescent endoscopy or Narrow Band imaging [16]. MB could also
be injected safely into peripheral lung nodules using navigational
bronchoscopy. This has been performed for subpleural localisation
of small tumors before thoracoscopy [17] In addition, methylene
blue has been succesfully applied to the in vivo microscopic imaging
of distal, intraparenchymal lesions of the lungs via the probe-based
confocal laser endomicroscopy technique and navigational bron-
choscopy, suggesting that the dye may  also be used for the PDT
treatment of distal lung tumors [18].
Altogether, our results suggests that intratumoral methylene
blue for PDT of superﬁcial bronchial cancers in humans could be
feasible. Evaluation of efﬁcacy and of potential advantages of local
utilization of MB-PDT (for example avoidance of skin protection
measures, better access of the photosensitizing agent, or cost-
effectiveness) will require speciﬁc dedicated studies.
5. Conclusion
In these experimental models, photodynamic therapy coupled
with the intratumoral injection of methylene blue appears to be an
efﬁcacious treatment for the local management of cancer lesions.
Further studies in humans are needed to assess its in vivo efﬁcacy
for the treatment of both superﬁcial bronchial cancers, and distal
lung cancers in inoperable patients.
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